Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
35 hedge funds and large institutions have $20.5M invested in Anthera Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 9 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
8% less funds holding
Funds holding: 38 → 35 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
42% less capital invested
Capital invested by funds: $35.3M → $20.5M (-$14.8M)
89% less call options, than puts
Call options by funds: $13K | Put options by funds: $121K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
+$2.19M |
| 2 |
BC
Broadfin Capital
New York
|
+$1.41M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$324K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$263K |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$263K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.16M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.18M |
| 3 |
MCM
Moore Capital Management
New York
|
-$678K |
| 4 |
Renaissance Technologies
New York
|
-$258K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$181K |
ANTH Hedge Fund Activity: Q3 2014 in Review
35 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q3 2014, worth a combined $20.5M — down 42% from $35.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ANTH and 6 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 13 added.
The largest buyer was Gruss Capital Management, adding an estimated $2.19M. The largest seller was OrbiMed, exiting entirely with an estimated $3.16M sold.
- 35 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q3 2014, down from 38 in Q2 2014.
- Funds reported $20.5M of Anthera Pharmaceuticals, Inc. stock for Q3 2014, down 42% quarter-over-quarter.
- 6 funds opened new Anthera Pharmaceuticals, Inc. positions in Q3 2014 and 9 closed out, a net change of -3 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q3 2014 was Gruss Capital Management, an estimated $2.19M added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q3 2014 was OrbiMed, an estimated $3.16M sold.
Based on aggregated 13F filings for Q3 2014.